| Dr Elijah G Miller, DO | |
|
201 Nw Rd Mize Road, Blue Springs, MO 64014 | |
| (816) 655-5426 | |
| (816) 655-5408 |
| Full Name | Dr Elijah G Miller |
|---|---|
| Gender | Male |
| Speciality | Orthopedic Surgery |
| Experience | 8 Years |
| Location | 201 Nw Rd Mize Road, Blue Springs, Missouri |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1386191682 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207X00000X | Orthopaedic Surgery | 2016023436 (Missouri) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Trinity Regional Medical Center | Fort dodge, IA | Hospital |
| Stewart Memorial Community Hospital | Lake city, IA | Hospital |
| Humboldt County Memorial Hospital | Humboldt, IA | Hospital |
| Friendship Haven, Inc | Fort dodge, IA | Nursing home |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Iowa Physicians Clinic Medical Foundation | 8729992318 | 972 |
| Stewart Memorial Community Hospital | 4486563707 | 27 |
News Archive
A sub-study of the Outcome Reduction with an Initial Glargine Intervention (ORIGIN) trial, designed to investigate the effect of insulin glargine and omega-3 fatty acids on atherosclerosis progression, has found that, compared to standard care, only insulin glargine (a long-acting insulin) had a "modest" statistically non-significant reducing effect on the primary outcome of rate of change in maximum carotid intima media thickness (CIMT) at 12 carotid sites.
One of the most challenging issues in cancer therapy is the development of drug resistance and subsequent disease progression.
Cephalon, Inc. today announced that it and its wholly-owned subsidiary CIMA LABS INC. have filed a lawsuit in U.S. District Court in Delaware against Watson Pharmaceuticals, Inc. and its wholly-owned subsidiary, Watson Laboratories, Inc., for infringement of U.S. Patent Nos. 6,200,604 and 6,974,590, which cover methods of use for the Cephalon product FENTORA(R) (fentanyl buccal tablet) [C-II].
Johns Hopkins scientists have published laboratory data refuting studies that suggest blood vessels that form within brain cancers are largely made up of cancer cells. The theory of cancer-based blood vessels calls into question the use and value of anticancer drugs that target these blood vessels, including bevacizumab (Avastin).
› Verified 8 days ago
| Entity Name | Stewart Memorial Community Hospital |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1285652909 PECOS PAC ID: 4486563707 Enrollment ID: O20031107000249 |
News Archive
A sub-study of the Outcome Reduction with an Initial Glargine Intervention (ORIGIN) trial, designed to investigate the effect of insulin glargine and omega-3 fatty acids on atherosclerosis progression, has found that, compared to standard care, only insulin glargine (a long-acting insulin) had a "modest" statistically non-significant reducing effect on the primary outcome of rate of change in maximum carotid intima media thickness (CIMT) at 12 carotid sites.
One of the most challenging issues in cancer therapy is the development of drug resistance and subsequent disease progression.
Cephalon, Inc. today announced that it and its wholly-owned subsidiary CIMA LABS INC. have filed a lawsuit in U.S. District Court in Delaware against Watson Pharmaceuticals, Inc. and its wholly-owned subsidiary, Watson Laboratories, Inc., for infringement of U.S. Patent Nos. 6,200,604 and 6,974,590, which cover methods of use for the Cephalon product FENTORA(R) (fentanyl buccal tablet) [C-II].
Johns Hopkins scientists have published laboratory data refuting studies that suggest blood vessels that form within brain cancers are largely made up of cancer cells. The theory of cancer-based blood vessels calls into question the use and value of anticancer drugs that target these blood vessels, including bevacizumab (Avastin).
› Verified 8 days ago
| Entity Name | Iowa Physicians Clinic Medical Foundation |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1366425274 PECOS PAC ID: 8729992318 Enrollment ID: O20031118000363 |
News Archive
A sub-study of the Outcome Reduction with an Initial Glargine Intervention (ORIGIN) trial, designed to investigate the effect of insulin glargine and omega-3 fatty acids on atherosclerosis progression, has found that, compared to standard care, only insulin glargine (a long-acting insulin) had a "modest" statistically non-significant reducing effect on the primary outcome of rate of change in maximum carotid intima media thickness (CIMT) at 12 carotid sites.
One of the most challenging issues in cancer therapy is the development of drug resistance and subsequent disease progression.
Cephalon, Inc. today announced that it and its wholly-owned subsidiary CIMA LABS INC. have filed a lawsuit in U.S. District Court in Delaware against Watson Pharmaceuticals, Inc. and its wholly-owned subsidiary, Watson Laboratories, Inc., for infringement of U.S. Patent Nos. 6,200,604 and 6,974,590, which cover methods of use for the Cephalon product FENTORA(R) (fentanyl buccal tablet) [C-II].
Johns Hopkins scientists have published laboratory data refuting studies that suggest blood vessels that form within brain cancers are largely made up of cancer cells. The theory of cancer-based blood vessels calls into question the use and value of anticancer drugs that target these blood vessels, including bevacizumab (Avastin).
› Verified 8 days ago
| Entity Name | Trinity Regional Medical Center |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1073594156 PECOS PAC ID: 7315858529 Enrollment ID: O20031204000921 |
News Archive
A sub-study of the Outcome Reduction with an Initial Glargine Intervention (ORIGIN) trial, designed to investigate the effect of insulin glargine and omega-3 fatty acids on atherosclerosis progression, has found that, compared to standard care, only insulin glargine (a long-acting insulin) had a "modest" statistically non-significant reducing effect on the primary outcome of rate of change in maximum carotid intima media thickness (CIMT) at 12 carotid sites.
One of the most challenging issues in cancer therapy is the development of drug resistance and subsequent disease progression.
Cephalon, Inc. today announced that it and its wholly-owned subsidiary CIMA LABS INC. have filed a lawsuit in U.S. District Court in Delaware against Watson Pharmaceuticals, Inc. and its wholly-owned subsidiary, Watson Laboratories, Inc., for infringement of U.S. Patent Nos. 6,200,604 and 6,974,590, which cover methods of use for the Cephalon product FENTORA(R) (fentanyl buccal tablet) [C-II].
Johns Hopkins scientists have published laboratory data refuting studies that suggest blood vessels that form within brain cancers are largely made up of cancer cells. The theory of cancer-based blood vessels calls into question the use and value of anticancer drugs that target these blood vessels, including bevacizumab (Avastin).
› Verified 8 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Elijah G Miller, DO 201 Nw Rd Mize Road, Blue Springs, MO 64014 Ph: (816) 655-5426 | Dr Elijah G Miller, DO 201 Nw Rd Mize Road, Blue Springs, MO 64014 Ph: (816) 655-5426 |
News Archive
A sub-study of the Outcome Reduction with an Initial Glargine Intervention (ORIGIN) trial, designed to investigate the effect of insulin glargine and omega-3 fatty acids on atherosclerosis progression, has found that, compared to standard care, only insulin glargine (a long-acting insulin) had a "modest" statistically non-significant reducing effect on the primary outcome of rate of change in maximum carotid intima media thickness (CIMT) at 12 carotid sites.
One of the most challenging issues in cancer therapy is the development of drug resistance and subsequent disease progression.
Cephalon, Inc. today announced that it and its wholly-owned subsidiary CIMA LABS INC. have filed a lawsuit in U.S. District Court in Delaware against Watson Pharmaceuticals, Inc. and its wholly-owned subsidiary, Watson Laboratories, Inc., for infringement of U.S. Patent Nos. 6,200,604 and 6,974,590, which cover methods of use for the Cephalon product FENTORA(R) (fentanyl buccal tablet) [C-II].
Johns Hopkins scientists have published laboratory data refuting studies that suggest blood vessels that form within brain cancers are largely made up of cancer cells. The theory of cancer-based blood vessels calls into question the use and value of anticancer drugs that target these blood vessels, including bevacizumab (Avastin).
› Verified 8 days ago
Dr. Angela K Walker, D.O. Orthopedic Surgery Medicare: Accepting Medicare Assignments Practice Location: 201 Nw R D Mize Rd, Blue Springs, MO 64014 Phone: 816-655-5426 Fax: 816-655-5408 | |
Dr. Derec Stanislav, DO Orthopedic Surgery Medicare: Medicare Enrolled Practice Location: 201 Nw Rd Mize Road, Blue Springs, MO 64014 Phone: 816-655-5426 Fax: 816-655-5408 | |
David W Dugan, D.O. Orthopedic Surgery Medicare: Accepting Medicare Assignments Practice Location: 203 Nw R. D. Mize Rd, Suite # 250, Blue Springs, MO 64014 Phone: 816-220-5123 Fax: 816-220-3085 | |
Kevin Andrew Witte, D.O. Orthopedic Surgery Medicare: Accepting Medicare Assignments Practice Location: 203 Nw R.d. Mize Rd, Ste 250, Blue Springs, MO 64014 Phone: 816-220-8727 Fax: 816-220-8269 | |
Michael Jason Justice, D.O. Orthopedic Surgery Medicare: Accepting Medicare Assignments Practice Location: 203 Nw Rd Mize Road, Suite #250, Blue Springs, MO 64014 Phone: 816-220-8727 Fax: 816-220-8269 | |
Dr. Katherine Paul, DO Orthopedic Surgery Medicare: Medicare Enrolled Practice Location: 201 Nw Rd Mize Road, Blue Springs, MO 64014 Phone: 816-220-8727 Fax: 816-220-8269 |